Editorial

• Volume 3 number 2 April–June 2010

Conference reports

• 17th Conference on Retroviruses and Opportunistic Infections, 16-10 February 2010, San Francisco

• Treatment reduces infections by over 90%: a theme that is here to stay

• ACTG 5205: atazanavir/ritonavir vs efavirenz in treatment naïve patients

• Pipeline compounds and new approaches to treatment

• Clinical benefits of stopping smoking: CVD and CHD risk returns to that of ‘previous smoker’ in HIV-positive people within three years

• HIV increases the risk of lung cancer, independent of smoking status

• HIV-positive people in the HOPS cohort have 4-fold risk of fracture compared to general population in the US

• OCTANE 2: nevirapine and lopinavir/r are similar when used with tenofovir and FTC in treatment-naïve women

• HIV incidence and retesting in pregnancy

• Efavirenz use in pregnancy and birth outcomes

• Pregnancy outcomes in women using non-AZT HAART in Europe

• When should HAART be initiated in pregnancy to achieve an undetectable viral load?

• Pregnancy outcomes in infants exposed to maternal antiretrovirals in utero

• Maternal TB, HIV and pregnancy

• Botswana IPT trial: Continuous isoniazid superior to 6 months short course

• 40th World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease 3-7 December 2009, Cancun, Mexico

• Cepheid Gene Xpert diagnostic technology for TB

• Adherence of TB patients on self-administered treatment

• High mortality and poor record keeping for TB in-patients in Kwazulu-Natal Hospital

• Factors affecting survival of XDR TB patients

Guidelines

• South African antiretroviral treatment guidelines updated

• WHO TB guidelines

• BHIVA draft guidelines for the treatment of opportunistic infections: online for comment

Treatment access

• FDA approval of generic ARVs

• Waiting lists grow in the US

• MSF criticise Abbott over new ritonavir formulation

TB coinfection

• TB screening algorithm to determine who can safely go onto IPT and who needs to be treated

• Analysis of the emergence of drug resistant TB in a South African mine

• Systematic review of rifamycin studies shows eight months might be beneficial

Basic science

• Early predictors of disease progression

• Sex and the single microbicide

• Baseline naïve CD4 T cell numbers predict the immunological response to ART

• Has poor CD4 T cell reconstitution in the gut been exaggerated?

On the web

• PLoS Medicine

PDFs

• Volume 3 Number 2 April-June 2010 PDF